Treatments for neurotoxicity in Alzheimer's Disease

Details Treatments for neurotoxicity in Alzheimer's Disease Treatments for neurotoxicity in Alzheimer's Disease

2006-06-27

2006-06-27

Celsa, Bennett (Department: 1639)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07067550

ABSTRACT:
The invention involves identification of a mechanism of β-amyloid peptide cytotoxicity, which enables treatment of conditions caused by β-amyloid peptide aggregates by administration of compounds which antagonize the mechanism of cytotoxicity. The invention includes the identification and isolation of compounds which can reduce the neurotoxic effects of such aggregates. Methods for treating conditions resulting from neurotoxic β-amyloid peptide aggregates, such as Alzheimer's disease and pharmaceutical preparations are provided. Also provided are methods for selecting additional compounds which can reduce the neurotoxic effects of β-amyloid aggregates.

REFERENCES:
patent: 4801575 (1989-01-01), Pardridge
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4918162 (1990-04-01), Slamon et al.
patent: 4933324 (1990-06-01), Shashoua
patent: 4975430 (1990-12-01), Jahr et al.
patent: 5004697 (1991-04-01), Pardridge
patent: 5108921 (1992-04-01), Low et al.
patent: 5112596 (1992-05-01), Malfroy-Camine
patent: 5268164 (1993-12-01), Kozarich et al.
patent: 5385915 (1995-01-01), Buxbaum et al.
patent: 5391723 (1995-02-01), Priest
patent: 5434050 (1995-07-01), Maggio et al.
patent: 5442043 (1995-08-01), Fukuta et al.
patent: 5491144 (1996-02-01), Trinks et al.
patent: 5506206 (1996-04-01), Kozarich et al.
patent: 5525727 (1996-06-01), Bodor
patent: 5527527 (1996-06-01), Friden
patent: 5552415 (1996-09-01), May
patent: 5552426 (1996-09-01), Lunn et al.
patent: 5576209 (1996-11-01), Bredesen
patent: 5639726 (1997-06-01), Lawrence et al.
patent: 5663336 (1997-09-01), Trinks et al.
patent: 5703129 (1997-12-01), Felsenstein et al.
patent: 5817626 (1998-10-01), Findeis et al.
patent: 5948763 (1999-09-01), Soto-Jara et al.
patent: 6172043 (2001-01-01), Ingram et al.
patent: 6552066 (2003-04-01), Sharpe et al.
patent: 2003/0105152 (2003-06-01), Ingram et al.
patent: 2003/0114510 (2003-06-01), Ingram et al.
patent: WO 96/37212 (1996-11-01), None
patent: PCT/US96/10220 (1996-12-01), None
patent: WO 98/08868 (1998-03-01), None
patent: WO 98/30229 (1998-07-01), None
Anwer et al.,Int. J. Pep. Protein Res. 36:392-399, 1990.
Arispe et al.,Proc. Nat'l Acad. Sci. USA90:10573-10577, 1993.
Arispe et al.,Proc. Nat'l Acad. Sci. USA90:567-571, 1993.
Blanchard et al.,Brain Res776(1-2):40-50, 1997.
Lam,Nature354:82-84, 1991.
Levine,Protein Sci2:404-410, 1993.
Mattson et al.,J. Neurosci. 12:376-389, 1992.
Nachman et al.,Regul. Pept. 57:359-370, 1995.
Rivera-Baeza et al.,Neuropeptides30:327-333, 1996.
Shen et al.,Biophys J. 65:2383-2395, 1993.
Soto et al.,Biochem. Biophys. Res. Commun. 226:672-680, 1996.
Spatola et al,Chemistry&Biochemistry of AA, Peptides&Proteins(Weinstein, Ed.) vol. 7, pp. 267-356, 1983.*.
Tomski and Murphy,Arch. Biochem. Biophys. 294:630-638, 1992.
Blanchard et al.,J. Alzheimer's Disease2(2):137-149 (2000).
Bräuner et al.,Biochim Biophys ActaApr. 11, 1984;771(2):208-16.
Cooper et al., Biochemistry. 29:3859-3865 (1990).
Durell et al.,Biophys. J. 67:2137-2145 (1994).
Hartinger,J. Biol. Chem. 268:23122-23127 (1993).
Hartley et al.,J. Neuroscience19:8876-8884 (1999).
Kawahara et al.,Biophys. J. 73:67-75 (1997).
Langheinrich, et al.,J. Physiol. 502 ( Pt 2):397-408 (1997).
Pollard et al.,Ann. N.Y. Acad. Sci. 695:165-168 (1993).
Sanderson et al.,Brain Res. 744:7-14 (1997).
Walsh et al.,J. Biol. Chem. 274:25945-52 (1999).
Yankner et al.,Science. 250:279-282 (1990).
O'Dell, T. J. et al., Nature vol. 353 (6344), (Sep. 1991) pp. 558-560.
Franco, R., et al., Eur. J. Physiol. vol. 442 (Jun. 2001) pp. 791-800.
Dieter, M.Z., et al., Biochemical Pharmacology, vol. 61(2) (Jan. 2001) pp. 215-225.
Tjernberg et al., Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. Apr. 12, 1996;271(15):8545-8.
Tjernberg et al., Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem. May 9, 1997;272(19):12601-5.

Affiliated with

Also associated with

Rating

Treatments for neurotoxicity in Alzheimer's Disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatments for neurotoxicity in Alzheimer's Disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatments for neurotoxicity in Alzheimer's Disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3698600